-transparent.png){kind=logo}
We have presented two cases of agranulocytosis occurring in patients receiving a combination antiarrhythmic regimen. As multiple drug therapy for ventricular arrhythmias becomes more commonplace, increased scrutiny should be given to agents chosen, in an effort to prevent any possible adverse interactions. When future cases are encountered, the acetylator pheontype should be determined. This information would aid in assessing the predicative value of the acetylator phenotype in the development of agranulocytosis. Due to the inherent danger, neither patient was rechallenged with procainamide nor phenytoin.
Related Publications
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
April 1984,
Annals of internal medicine,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
October 1974,
European journal of clinical pharmacology,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
June 1984,
Annals of internal medicine,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
January 1982,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
December 1984,
Southern medical journal,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
February 1979,
Archives of internal medicine,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
August 1969,
American heart journal,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
May 1972,
Scottish medical journal,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
December 1977,
American journal of hospital pharmacy,
J E Crook, and
R L Woosley, and
R B Leftwich, and
E A Natelson
June 1978,
Ugeskrift for laeger,
